WP1874 / CNS Pharma, UT MD Anderson Cancer Center - LARVOL DELTA

CNS Pharmaceuticals Reports Full Year 2021 Financial Results and Provides Corporate Update (PRNewswire) - "The Company's development work has produced a new mesylate salt of WP1244, now identified as WP1874. The enhanced solubility of this salt may increase its ability to be formulated for use in an IV infusion, while maintaining similar potency and toxicity characteristics. Going forward, WP1874 will be the primary focus in our development efforts of the WP1244 portfolio. CNS Pharmaceuticals is also evaluating the use of WP1244/WP1874 in the treatment of other primary brain and central nervous system cancers, as well as cancers metastatic to the brain including pancreatic, ovarian, and lymphomas...Upcoming Milestones....File IND in 2023."

IND • Pipeline update • Brain Cancer • CNS Tumor • Oncology • Solid Tumor